TransMedics Group, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Josh Jennings from TD Cowen reiterated a Buy rating on the stock and has a $190.00 price target.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Josh Jennings has given his Buy rating due to a combination of factors tied to TransMedics’ strengthening competitive position in heart and lung transplantation. After attending ISHLT 2026 and engaging with management, he believes the OCS Heart and OCS Lung platforms are poised to benefit meaningfully from the company’s next wave of rigorous clinical trials, including ENHANCE and DENOVO, which are designed to expand adoption and validate superiority versus legacy methods.
He also views TransMedics’ strategy to set a new benchmark for evidence in organ preservation as a key long-term value driver, as the firm moves from simply leading randomized studies to redefining gold-standard trial design with blinded randomization and standardized controls. In Jennings’s assessment, this methodical approach to generating FDA-grade data on normothermic perfusion versus static cold storage should not only clarify clinical outcomes but also reinforce TransMedics’ leadership, supporting sustained growth and justifying a Buy recommendation.
In another report released on April 22, Needham also maintained a Buy rating on the stock with a $174.00 price target.
Based on the recent corporate insider activity of 32 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of TMDX in relation to earlier this year.